- SNMMI Henry N. Wagner, Jr., Abstract of
the Year award represents top selection out of more than 1,500
abstracts accepted for presentation
NEW
YORK, June 26, 2023 /PRNewswire/ -- Actinium
Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM, 'Actinium'), a leader
in the development of targeted radiotherapies, today announced that
the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2023
Annual Meeting selected Abstract 685 titled "Individualized dosing
for high-dose targeted radiation of hematopoietic cells with
Iomab-B (I131-apamistamab) prior to HCT in relapsed/refractory
acute myeloid leukemia (R/R AML): Safety and efficacy results from
the pivotal phase 3 SIERRA trial" as the Abstract of the Year.
"It is a great honor for this SIERRA data abstract and this
team of esteemed abstract authors to have received this award
highlighting Iomab-B's potential for people with relapsed and
refractory AML," said Sandesh
Seth, Chairman and Chief Executive Officer. "Today's
SNMMI honor represents the fourth oral presentation of the SIERRA
trial data at prestigious medical conferences in 2023, including
TCT, EBMT, and EHA. The extensive global recognition of the SIERRA
results highlights Iomab-B's potential to transform outcomes for
the significant number of people with relapsed or refractory AML by
enabling increased access to bone marrow transplant via a targeted
radiotherapeutic. We are committed to file our BLA submission with
U.S. Food and Drug Administration in the second half of this year
in our endeavor to bring this new radiotherapeutic to people with
great need."
"Elderly patients with active, relapsed/refractory AML have
a very poor prognosis and currently have very limited treatment
options. In routine clinical practice, these patients are not being
considered for potentially curative bone marrow transplant," said
Neeta Pandit-Taskar, MD, lead
abstract author, attending physician, Molecular Imaging and Therapy
Service, in the Department of Radiology at Memorial Sloan Kettering
Cancer Center, and professor at Weill Cornell Medical College, in
New York, New York. "This pivotal
study showed that a single personalized dose of Iomab-B
enabled all patients who received the therapeutic dose to have
access to potentially curative bone marrow transplant, compared to
only 17 percent of patients who received conventional care. Iomab-B
also demonstrated long-term survival benefit for patients who met
the primary endpoint, and safety of the Iomab-B led regimen was
excellent. In addition, the visibility and cross-functionality of
nuclear medicine was clearly demonstrated, strengthening the
collaborative effort between nuclear medicine, nursing, and
transplant teams. This will add further growth and impetus to use
of nuclear medicine in planning and administration
of theranostic radioimmunotargeted therapy."
AML is one of the most lethal forms of leukemia in adults. The
American Cancer Society estimates that 20,380 people will be
diagnosed with AML and more than 11,300 will die from the disease
in 2023. Patients with relapsed or refractory disease represent the
largest segment of AML patients.
About Actinium
Actinium develops targeted radiotherapies to meaningfully
improve survival for people who have failed existing oncology
therapies. Advanced pipeline candidates Iomab-B (pre-BLA), an
induction and conditioning agent prior to bone marrow transplant,
and Actimab-A (National Cancer Institute CRADA pivotal development
path), a therapeutic, have demonstrated potential to extend
survival outcomes for people with relapsed and refractory acute
myeloid leukemia. Actinium plans to advance Iomab-B for other
blood cancers and next generation conditioning candidate Iomab-ACT
to improve cell and gene therapy outcomes. Actinium's technology
platform is the basis for collaborations with Astellas Pharma
for solid tumors, AVEO Oncology/LG Chem Life Sciences for HER3
solid tumors, and EpicentRx for its CD47 targeting agent, and
several internal programs in solid tumors. Actinium holds more than
200 patents and patent applications.
For more information, please visit:
https://www.actiniumpharma.com/
Contact:
Matthew
Beck
Vice President Investor Relations & Communications
mbeck@actiniumpharma.com
(917) 415-1750
View original content to download
multimedia:https://www.prnewswire.com/news-releases/snmmi-2023-annual-meeting-abstract-of-the-year-awarded-to-actiniums-iomab-b-phase-3-sierra-data-301862644.html
SOURCE Actinium Pharmaceuticals, Inc.